| Stereochemistry | ABSOLUTE |
| Molecular Formula | C15H19N3OS.ClH |
| Molecular Weight | 325.857 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CC(C)C(=O)NC1=CC=CC(=C1)[C@H]2CN3CCSC3=N2
InChI
InChIKey=FXYKKPLSQTYWRY-BTQNPOSSSA-N
InChI=1S/C15H19N3OS.ClH/c1-10(2)14(19)16-12-5-3-4-11(8-12)13-9-18-6-7-20-15(18)17-13;/h3-5,8,10,13H,6-7,9H2,1-2H3,(H,16,19);1H/t13-;/m1./s1
Butamisole is an injectable imidazothiazoles anthelmintic. In dogs it is used for the treatment of infections with whipworms (Trichuris vulpis ), and the hookworm (Ancylostoma caninum ). Nicotinic acetylcholine receptor agonist. Acts as agonist at nicotinic Ach receptor of nematode à ganglionic stimulation causes sustained muscle contraction initially followed by depolarising neuro muscular blockade which in turn leads to spastic paralysis.
Originator
Approval Year
PubMed
Patents
Sample Use Guides
Dogs: Administer 0.1 mg per pound of body weight by subcutaneous injection. In problem cases, retreatment for whipworms may be necessary in approximately 3 months. For hookworms, a second injection should be given 21 days after the initial treatment.
Route of Administration:
Other
Butamisole was without agonist actions on either alpha7 or ACR-16 chicken nicotinic receptors in the range 10nM-1mM. However, butamisole (pIC(50)=4.9 for both alpha7 and ACR-16) antagonized responses of both alpha7 and ACR-16 receptors to acetylcholine. Application of butamisole
in the concentration range 0.1 um-100 um for 30 s prior
to application of 1 mM ACh in the continued presence of
butamisole resulted in a dose-dependent reduction in the
ACh current amplitude recorded from both receptors.
ACTIVE MOIETY
SUBSTANCE RECORD
